drugset / Trial / NCT04608331

Dexmedetomidine Supplemented Analgesia in Patients at High-risk of Obstructive Sleep Apnea

NCT04608331 ↗

Phase 4 Completed 152 enrolled Peking University First Hospital
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Obstructive sleep apnea (OSA) is a common sleep disturbance that can cause intermittent hypoxia, hypercapnia, and sleep structure disorders. The presence of OSA is associated with worse outcomes after surgery including increased incidence of complications. High-flow nasal cannula (HFNC) therapy can improve oxygenation of OSA patients by maintaining a certain positive pressure in the nasopharyngeal cavity. Previous studies showed that, dexmedetomidine supplemented analgesia can improve sleep quality and pain relief. The investigators hypothesize that, for high-risk OSA patients following major non-cardiac surgery with HFNC therapy, dexmedetomidine supplemented analgesia can improve sleep quality. The purpose of this pilot randomized controlled trial is to investigate the impact of dexmedetomidine supplemented analgesia on sleep quality in high-risk OSA patients after major non-cardiac surgery.

Timeline

Start
2021-01-29
Primary completion
2022-08-17
Completion
2022-09-20

Outcome

Met primary endpoint

paper Mini-dose dexmedetomidine supplemented analgesia increased the percentage of stage N2 sleep (median difference, 10%; 95% CI, 1 to 21%; p = 0.029); PMID 39416950 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 1.25 ug/ml —